To receive free CE credit, please complete the four modules to the left and then proceed to the post test and evaluation.

 Activity Description

Parkinson disease psychosis (PDP) is common among long-term care residents with Parkinson disease. If left untreated, or treated inappropriately, residents are at risk of worsening symptoms, reduced psychosocial functioning, hospitalization, and death. Recognizing the signs and symptoms of PDP early can reduce adverse outcomes, and effective communication with residents, families, and other staff members is an integral part of the process. Treatment of PDP requires a stepwise approach that takes into consideration secondary causes, nonpharmacologic options, medication optimization, and antipsychotic agents. Many of these steps are addressed in the recently updated Centers for Medicare & Medicaid Services (CMS) Mega-Rule. The desired result of this multicomponent activity is for clinicians in the long-term care setting to identify PDP early and create evidence-based, CMS-compliant pharmacologic treatment plans that consider motor and nonmotor symptoms for residents with Parkinson disease. To facilitate a team effort to better identify and manage PDP, a four-page in-service tool was developed and is available here. [this will need to hyper link to the in-service tool on AADNS website.]

Target Audience

This activity is intended for directors of nursing, minimum data set nurses, and certified nurse administrators overseeing the care of residents with PDP.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify the signs and symptoms of PDP
  • Develop communication strategies to ask residents and caregivers about psychosis in patient-friendly appropriate language
  • Contrast individualized pharmacologic treatment plans for residents with PDP in the long-term care setting
  • Interpret new CMS requirements for the management of residents with PDP

Release date: Nov. 15, 2018
Expiration date: Nov. 30, 2019   

Faculty 

    Fay Hardison Bembry, RN, MSN, FNP-BC, PMHNP-BC (Co-Chair)
Psychiatric Mental Health Nurse Practitioner
Team Health Behavioral Health Services
Johnson City, Tennessee
      Beth Florczak, MS, RN, WCC, RAC-CT (Co-Chair)
Post-Acute Care Nurse Executive
Chicago, Illinois 
             
   

Matthew Menza, MD
Professor, Psychiatry and Neurology
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

      Dana Saffel, PharmD
President and CEO
PharmaCare Strategies, Inc
Santa Rosa Beach, Florida

             
    Paula McFeely Wiener, MSW, LCSW
Senior Parkinson Disease Information Specialist
Parkinson’s Foundation
Chicago, Illinois
       

Nursing Continuing Education

The American Association of Post-Acute Care Nursing is accredited by the American Nurses Credentialing Center to provide continuing nursing education. The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Disclosure of Conflicts of Interest

The American Association of Post-Acute Care Nursing requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

  • Fay Hardison Bembry, RN, MSN, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speakers Bureau: ACADIA Pharmaceuticals Inc; and Avanir Pharmaceuticals, Inc.
  • Beth Florczak, MS, RN, has nothing to disclose.
  • Matthew Menza, MD, had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: ACADIA Pharmaceuticals Inc.
  • Dana Saffel, PharmD, had a financial agreement or affiliation during the past year with the following commercial interest in the form of Speakers Bureau: ACADIA Pharmaceuticals Inc; Consultant: ACADIA Pharmaceuticals Inc.
  • Paula McFeely Wiener, MSW, LCSW, has nothing to disclose.

 The planners and managers have nothing to disclose.

 Method of Participation and Instructions for Credit

During the period Nov. 15, 2018, through Nov. 30, 2019, you must (1) read the learning objectives and disclosures; (2) study the educational activity; and (3) complete the post test with a score of 75% or better and the activity evaluation. Once you complete the online evaluation, your certificate will be made available immediately. Click on View Certificate and print the certificate for your records.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the American Association of Post-Acute Care Nursing, MedEdicus LLC, or ACADIA Pharmaceuticals Inc.

This activity is jointly provided by the American Association of Post-Acute Care Nursing and MedEdicus LLC.

   
This activity is supported by an independent educational grant from ACADIA Pharmaceuticals Inc.

This CE activity is copyrighted to MedEdicus LLC ©2018. All rights reserved. 168